You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Therapy Areas: Cardiovascular
Eli Lilly launches Foundayo weight‑loss pill in the US
Login
Username:

Password:


Related Headlines

Thryv Therapeutics doses first patients in Wave II clinical study for Long QT Syndrome; THRV-1268 receives FDA Fast Track Designation

Ondine Biomedical abstracts selected for 2026 World Congress on Infectious Diseases

Philips secures FDA clearance for Spectral CT Verida system

Eli Lilly launches Foundayo weight‑loss pill in the US

Lilly's Foundayo (orforglipron) weight loss pill gains US FDA approval

Hengrui Pharma and Braveheart Bio report positive Phase 2 results for HRS/BHB-1893 in oHCM

Amgen reports Repatha (evolocumab) cuts risk of first major CV events by 31% in high-risk patients without known significant atherosclerosis

GE HealthCare's Photonova Spectra gains FDA clearance

IsomAb names new CEO

Nuwellis completes Rendiatech acquisition

HeartBeam and Mount Sinai partner to advance AI-enabled cardiac monitoring

Medicomp Systems client IJN in Malaysia granted Stage 7 validation from HIMSS EMRAM

Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD

GAIA and Daiichi Sankyo Europe partner on digital therapeutic for cardiovascular care

Esperion to acquire Corstasis, expanding cardiovascular portfolio

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026